Dianthus Therapeutics Files 8-K

Ticker: DNTH · Form: 8-K · Filed: Nov 3, 2025 · CIK: 1690585

Dianthus Therapeutics, INC. /De/ 8-K Filing Summary
FieldDetail
CompanyDianthus Therapeutics, INC. /De/ (DNTH)
Form Type8-K
Filed DateNov 3, 2025
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, 8-k

TL;DR

Dianthus Therapeutics filed an 8-K, check for updates.

AI Summary

On November 3, 2025, Dianthus Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specific financial figures or significant business events were detailed in the provided excerpt.

Why It Matters

This filing indicates Dianthus Therapeutics is making a regulatory submission to the SEC, which could contain important updates for investors.

Risk Assessment

Risk Level: low — The filing is a routine SEC disclosure without immediate negative or positive financial implications presented in the excerpt.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Dianthus Therapeutics, Inc.?

The filing is primarily for "Other Events" and "Financial Statements and Exhibits" as reported on November 3, 2025.

What is the exact date of the report filed by Dianthus Therapeutics, Inc.?

The date of the report is November 3, 2025.

In which state is Dianthus Therapeutics, Inc. incorporated?

Dianthus Therapeutics, Inc. is incorporated in Delaware.

What is the principal executive office address for Dianthus Therapeutics, Inc.?

The principal executive office is located at 7 Times Square, 43rd Floor, New York, New York, 10036.

What is the registrant's telephone number as listed in the filing?

The registrant's telephone number is (929) 999-4055.

Filing Stats: 472 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2025-11-03 13:04:56

Key Financial Figures

Filing Documents

01 Other Events

Item 8.01 Other Events. On November 3, 2025, Dianthus Therapeutics, Inc. posted an updated corporate presentation (the "Presentation") on the investor relations section of its website. The Presentation is filed as Exhibit 99.1 and is incorporated by reference into this Item 8.01. Cautionary Note Regarding Forward-Looking Statements. The Presentation contains forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ materially from those expressed or implied by these statements. Please refer to the cautionary notes in the Presentation regarding these forward-looking statements.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Corporate Presentation of Dianthus Therapeutics, Inc., dated November 2025 104 Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DIANTHUS THERAPEUTICS, INC. Date: November 3, 2025 By: /s/ Adam M. Veness, Esq. Adam M. Veness, Esq. SVP, General Counsel and Secretary

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing